Related Experiment Video
Updated: Jul 1, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood
Daniel S Graciaa1, Hans P Verkerke2, Jeannette Guarner2
1Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Abstract:
We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January-March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.
Related Concept Videos
Coronavirus
Respiratory Syncytial Virus Disease

